Matches in SemOpenAlex for { <https://semopenalex.org/work/W1996881061> ?p ?o ?g. }
Showing items 1 to 100 of
100
with 100 items per page.
- W1996881061 abstract "Background: Combining proteasome inhibition with HDAC inhibition has recently been shown to provide synergistic anti‐tumor activity in preclinical and clinical studies. A proposed mechanism centers around inhibition of both of the major protein disposal mechanisms of the cell, resulting in near complete lack of ability of the tumor to dispose of normal pro‐apoptotic and growth inhibitory peptides. The bi‐cyclic structure of NPI‐0052 is not polypeptide based as are other proteasome inhibitors, leading to rapid, broad and prolonged inhibition of all 3 proteolytic sites, with unique proteasome inhibition, toxicology and efficacy profiles. Preclinical studies indicated marked synergy with a number of HDAC inhibitors in solid tumor and hematologic malignancy models. Materials and Methods: Patients with melanoma, pancreatic carcinoma and NSCLC having failed standard therapies were given NPI‐0052 intravenously on a weekly (Days 1, 8 and 15) schedule dose escalation, in combination with vorinostat 300 mg orally on the first 16 days of each 28 day cycle. A 3+3 design was used with the dose of NPI‐0052 escalated from 0.15 mg/m2 to 0.7 mg/m2. In addition to standard safety laboratory studies, proteasome inhibition and pharmacokinetics are also assayed in blood on Day 1 and multiple subsequent time points. Results: 20 patients have been enrolled into this study. There has not been an indication of increased toxicity with the combination, and the dose of NPI‐0052 has been escalated to and is currently being administered at the full single agent dose without dose limiting toxicity. Pharmacokinetic data indicate a short half life of NPI‐0052 ( Conclusions: The combination of full dose NPI‐0052 with vorinostat is tolerable and has not resulted in unexpected safety findings (of note the toxicity profile is dissimilar to that reported with other proteasome inhibitors, in not inducing neutropenia, thrombocytopenia or peripheral neuropathy). Pharmacokinetic and pharmacodynamic results were likewise consistent with what are expected from prior data with each drug. Enrollment continues to further characterize the combination at the recommended phase 2 dose. Citation Information: Mol Cancer Ther 2009;8(12 Suppl):A107." @default.
- W1996881061 created "2016-06-24" @default.
- W1996881061 creator A5000260833 @default.
- W1996881061 creator A5000933764 @default.
- W1996881061 creator A5006028057 @default.
- W1996881061 creator A5010455810 @default.
- W1996881061 creator A5018153995 @default.
- W1996881061 creator A5026301702 @default.
- W1996881061 creator A5050012997 @default.
- W1996881061 creator A5061460550 @default.
- W1996881061 creator A5070238121 @default.
- W1996881061 creator A5079833339 @default.
- W1996881061 date "2009-12-10" @default.
- W1996881061 modified "2023-09-26" @default.
- W1996881061 title "Abstract A107: Clinical trial combining proteasome (NPI‐0052) and HDAC (vorinostat) inhibition in melanoma, pancreatic, and lung cancer" @default.
- W1996881061 doi "https://doi.org/10.1158/1535-7163.targ-09-a107" @default.
- W1996881061 hasPublicationYear "2009" @default.
- W1996881061 type Work @default.
- W1996881061 sameAs 1996881061 @default.
- W1996881061 citedByCount "1" @default.
- W1996881061 crossrefType "proceedings-article" @default.
- W1996881061 hasAuthorship W1996881061A5000260833 @default.
- W1996881061 hasAuthorship W1996881061A5000933764 @default.
- W1996881061 hasAuthorship W1996881061A5006028057 @default.
- W1996881061 hasAuthorship W1996881061A5010455810 @default.
- W1996881061 hasAuthorship W1996881061A5018153995 @default.
- W1996881061 hasAuthorship W1996881061A5026301702 @default.
- W1996881061 hasAuthorship W1996881061A5050012997 @default.
- W1996881061 hasAuthorship W1996881061A5061460550 @default.
- W1996881061 hasAuthorship W1996881061A5070238121 @default.
- W1996881061 hasAuthorship W1996881061A5079833339 @default.
- W1996881061 hasConcept C104317684 @default.
- W1996881061 hasConcept C112705442 @default.
- W1996881061 hasConcept C121608353 @default.
- W1996881061 hasConcept C126322002 @default.
- W1996881061 hasConcept C143998085 @default.
- W1996881061 hasConcept C185592680 @default.
- W1996881061 hasConcept C197934379 @default.
- W1996881061 hasConcept C27740335 @default.
- W1996881061 hasConcept C2776256026 @default.
- W1996881061 hasConcept C2776262904 @default.
- W1996881061 hasConcept C2776364478 @default.
- W1996881061 hasConcept C2778305200 @default.
- W1996881061 hasConcept C2778367456 @default.
- W1996881061 hasConcept C2778375690 @default.
- W1996881061 hasConcept C2780210213 @default.
- W1996881061 hasConcept C29730261 @default.
- W1996881061 hasConcept C502942594 @default.
- W1996881061 hasConcept C55493867 @default.
- W1996881061 hasConcept C64927066 @default.
- W1996881061 hasConcept C71924100 @default.
- W1996881061 hasConcept C98274493 @default.
- W1996881061 hasConceptScore W1996881061C104317684 @default.
- W1996881061 hasConceptScore W1996881061C112705442 @default.
- W1996881061 hasConceptScore W1996881061C121608353 @default.
- W1996881061 hasConceptScore W1996881061C126322002 @default.
- W1996881061 hasConceptScore W1996881061C143998085 @default.
- W1996881061 hasConceptScore W1996881061C185592680 @default.
- W1996881061 hasConceptScore W1996881061C197934379 @default.
- W1996881061 hasConceptScore W1996881061C27740335 @default.
- W1996881061 hasConceptScore W1996881061C2776256026 @default.
- W1996881061 hasConceptScore W1996881061C2776262904 @default.
- W1996881061 hasConceptScore W1996881061C2776364478 @default.
- W1996881061 hasConceptScore W1996881061C2778305200 @default.
- W1996881061 hasConceptScore W1996881061C2778367456 @default.
- W1996881061 hasConceptScore W1996881061C2778375690 @default.
- W1996881061 hasConceptScore W1996881061C2780210213 @default.
- W1996881061 hasConceptScore W1996881061C29730261 @default.
- W1996881061 hasConceptScore W1996881061C502942594 @default.
- W1996881061 hasConceptScore W1996881061C55493867 @default.
- W1996881061 hasConceptScore W1996881061C64927066 @default.
- W1996881061 hasConceptScore W1996881061C71924100 @default.
- W1996881061 hasConceptScore W1996881061C98274493 @default.
- W1996881061 hasLocation W19968810611 @default.
- W1996881061 hasOpenAccess W1996881061 @default.
- W1996881061 hasPrimaryLocation W19968810611 @default.
- W1996881061 hasRelatedWork W1533769407 @default.
- W1996881061 hasRelatedWork W1563699564 @default.
- W1996881061 hasRelatedWork W1580444165 @default.
- W1996881061 hasRelatedWork W1595109869 @default.
- W1996881061 hasRelatedWork W1608798960 @default.
- W1996881061 hasRelatedWork W1973245653 @default.
- W1996881061 hasRelatedWork W2056181814 @default.
- W1996881061 hasRelatedWork W2093255555 @default.
- W1996881061 hasRelatedWork W2117157820 @default.
- W1996881061 hasRelatedWork W2241828025 @default.
- W1996881061 hasRelatedWork W2253778139 @default.
- W1996881061 hasRelatedWork W2417464115 @default.
- W1996881061 hasRelatedWork W2564340835 @default.
- W1996881061 hasRelatedWork W2597441329 @default.
- W1996881061 hasRelatedWork W2613025114 @default.
- W1996881061 hasRelatedWork W2979309128 @default.
- W1996881061 hasRelatedWork W2979589406 @default.
- W1996881061 hasRelatedWork W3159718164 @default.
- W1996881061 hasRelatedWork W3187991411 @default.
- W1996881061 hasRelatedWork W606900738 @default.
- W1996881061 isParatext "false" @default.
- W1996881061 isRetracted "false" @default.
- W1996881061 magId "1996881061" @default.
- W1996881061 workType "article" @default.